Omega Therapeutics Inc. Common Stock

Omega Therapeutics Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases such as neutrophilic asthma acute respiratory distress syndrome dermatological oncology and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition the company develops OEC candidates for the treatment of alopecia a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics Inc. was incorporated in 2016 and is headquartered in Cambridge Massachusetts.